Vitrakvi (Larotrectinib)November 27, 2018
The neurotrophic receptor tyrosine kinase (NTRK) genes NTRK1, NTRK2, and NTRK 3 encode tropomyosin receptor kinase (TRK) proteins TRKA, TRKB, and TRKC, respectively. TRK fusions are genetic alternations that trigger oncogenic transformations; they occur when 1 of the NTRK genes becomes abnormally connected to another unrelated gene. Vitrakvi is a pan-TRK inhibitor. It is now the second drug approved by the FDA for a tumor-agnostic indication.
If you have a Hayes login, click here to view the full report on the Knowledge Center.